Clinical Trial Update: A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating lebekizumab (LY3650150) plus topical corticosteroids in Japanese adults with moderate-to-severe atopic dermatitis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Dermatitis, Atopic, Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2023-08-23